New criteria for sepsis-induced coagulopathy (SIC) following the revised sepsis definition: a retrospective analysis of a nationwide survey

Toshiaki Iba, Marcello Di Nisio, Jerrold H Levy, Naoya Kitamura, Jecko Thachil, Toshiaki Iba, Marcello Di Nisio, Jerrold H Levy, Naoya Kitamura, Jecko Thachil

Abstract

Objective: Recent clinical studies have shown that anticoagulant therapy might be effective only in specific at-risk subgroups of patients with sepsis and coagulation dysfunction. The definition of sepsis was recently modified, and as such, old scoring systems may no longer be appropriate for the diagnosis of sepsis-associated coagulopathy. The aim of this study was to evaluate prognostic factors in patients diagnosed with sepsis and coagulopathy according to the new sepsis definition and assess their accuracy in comparison with existing models.

Design: Retrospective analysis of the nationwide survey for recombinant human soluble thrombomodulin.

Setting: General emergency and critical care centres in secondary and tertiary care hospitals.

Participants: We evaluated the prognostic value of the newly proposed diagnostic criteria for sepsis-induced coagulopathy (SIC). A total of 1498 Japanese patients with sepsis and coagulopathy complications who were treated with recombinant thrombomodulin were analysed in this study.

Main outcome measures: The platelet count, prothrombin time (PT) ratio, fibrinogen/fibrin degradation products, systemic inflammatory response syndrome score and Sequential Organ Failure Assessment (SOFA) score obtained just before the start of treatment were examined in relation to the 28-day mortality rate.

Results: The platelet count, PT ratio and total SOFA were independent predictors of a fatal outcome in a logistic regression model. A SIC score was defined using the three above-mentioned variables with a positivity threshold of 4 points or more. The SIC score predicted higher 28-day mortality rate compared with the current Japanese Association for Acute Medicine-disseminated intravascular coagulation score (38.4%vs34.7%).

Conclusion: The SIC score is based on readily available parameters, is easy to calculate and has a high predictive value for 28-day mortality. Future studies are warranted to evaluate whether the SIC score may guide the decision to initiate anticoagulant therapy.

Keywords: disseminated intravascular coagulation; platelet count; prothrombin time; sepsis; thrombomodulin.

Conflict of interest statement

Competing interests: NK is an employee of Asahi Kasei Pharma.

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Figures

Figure 1
Figure 1
Patient counts and mortality rates according to platelet count, prothrombin time ratio and total Sequential Organ Failure Assessment (SOFA) score. The bar graph shows the number of patients in each category, and the line graph represents the mortality rate. The x-axis represents the score and (case number). A: many of the patients had an initial platelet count of 100×109/L or less. Mortality increased to 35% when the count decreased to less than 100×109/L. B: mortality increased along with an increase in the prothrombin time ratio, reaching more than 40% when the prothrombin time ratio was more than 1.4. C: the population of total SOFA score of 0 and 1 is quite limited, and the mortality of this population was lower than that of the score of 2 or more.
Figure 2
Figure 2
Patient counts and mortality rates according to the SIC and the JAAM-DIC classifications. The patient distributions (bars) and the mortality rates (lines) are plotted according to the SIC scores (left) and the JAAM-DIC scores (right). The x-axis represents the score and (case number). The mortality rate increased as SIC score elevated and exceeded 20% at a score of 4. In contrast, the mortality rate exceeded 30% at a JAAM-DIC score of 4 and gradually increased to 40%. DIC, disseminated intravascular coagulation; JAAM, Japanese Association for Acute Medicine; SIC, sepsis-induced coagulopathy.

References

    1. Gando S, Levi M, Toh CH. Disseminated intravascular coagulation. Nat Rev Dis Primers 2016;2:16037 10.1038/nrdp.2016.37
    1. Dhainaut JF, Yan SB, Joyce DE, et al. . Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. J Thromb Haemost 2004;2:1924–33. 10.1111/j.1538-7836.2004.00955.x
    1. Kadri SS, Rhee C, Strich JR, et al. . Estimating ten-year trends in septic shock incidence and mortality in United States academic medical centers using clinical data. Chest 2017;151:278–85. 10.1016/j.chest.2016.07.010
    1. Dellinger RP, Levy MM, Rhodes A, et al. . Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013;41:580–637. 10.1097/CCM.0b013e31827e83af
    1. Kobayashi N, Maekawa T, Takada M, et al. . Criteria for diagnosis of DIC based on the analysis of clinical and laboratory findings in 345 DIC patients collected by the Research Committee on DIC in Japan. Bibl Haematol 1983;49:265–75.
    1. Taylor FB, Toh CH, Hoots WK, et al. . Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 2001;86:1327–30.
    1. Gando S, Iba T, Eguchi Y, et al. . A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients: comparing current criteria. Crit Care Med 2006;34:625–31. 10.1097/01.CCM.0000202209.42491.38
    1. Levi M, Ten Cate H. Disseminated intravascular coagulation. N Engl J Med 1999;341:586–92. 10.1056/NEJM199908193410807
    1. Gando S, Meziani F, Levi M. What’s new in the diagnostic criteria of disseminated intravascular coagulation? Intensive Care Med 2016;42:1062–4. 10.1007/s00134-016-4257-z
    1. Singer M, Deutschman CS, Seymour CW, et al. . The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016;315:801–10. 10.1001/jama.2016.0287
    1. Mimuro J, Takahashi H, Kitajima I, et al. . Impact of recombinant soluble thrombomodulin (thrombomodulin alfa) on disseminated intravascular coagulation. Thromb Res 2013;131:436–43. 10.1016/j.thromres.2013.03.008
    1. Bone RC, Balk RA, Cerra FB, et al. . Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992;101:1644–55.
    1. Vincent JL, A deMa, Cantraine F, et al. . Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Crit Care Med 1998;26:1793–800.
    1. Esmon CT, Xu J, Lupu F. Innate immunity and coagulation. J Thromb Haemost 2011;9 (Suppl 1):182–8. 10.1111/j.1538-7836.2011.04323.x
    1. Seong SY, Matzinger P. Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses. Nat Rev Immunol 2004;4:469–78. 10.1038/nri1372
    1. Liaw PC, Ito T, Iba T, et al. . DAMP and DIC: The role of extracellular DNA and DNA-binding proteins in the pathogenesis of DIC. Blood Rev 2016;30:257–61. 10.1016/j.blre.2015.12.004
    1. Schouten M, Wiersinga WJ, Levi M, et al. . Inflammation, endothelium, and coagulation in sepsis. J Leukoc Biol 2008;83:536–45. 10.1189/jlb.0607373
    1. Warren BL, Eid A, Singer P, et al. . Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001;286:1869–78.
    1. Ranieri VM, Thompson BT, Barie PS, et al. . Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 2012;366:2055–64. 10.1056/NEJMoa1202290
    1. Kienast J, Juers M, Wiedermann CJ, et al. . Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J Thromb Haemost 2006;4:90–7. 10.1111/j.1538-7836.2005.01697.x
    1. Umemura Y, Yamakawa K, Ogura H, et al. . Efficacy and safety of anticoagulant therapy in three specific populations with sepsis: a meta-analysis of randomized controlled trials. J Thromb Haemost 2016;14:518–30. 10.1111/jth.13230
    1. Yamakawa K, Umemura Y, Hayakawa M, et al. . Benefit profile of anticoagulant therapy in sepsis: a nationwide multicentre registry in Japan. Crit Care 2016;20:229 10.1186/s13054-016-1415-1
    1. Yamakawa K, Aihara M, Ogura H, et al. . Recombinant human soluble thrombomodulin in severe sepsis: a systematic review and meta-analysis. J Thromb Haemost 2015;13:508–19. 10.1111/jth.12841
    1. Vincent JL, Ramesh MK, Ernest D, et al. . A randomized, double-blind, placebo-controlled, Phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation. Crit Care Med 2013;41:2069–79. 10.1097/CCM.0b013e31828e9b03
    1. Tagami T, Matsui H, Horiguchi H, et al. . Recombinant human soluble thrombomodulin and mortality in severe pneumonia patients with sepsis-associated disseminated intravascular coagulation: an observational nationwide study. J Thromb Haemost 2015;13:31–40. 10.1111/jth.12786
    1. Yoshimura J, Yamakawa K, Ogura H, et al. . Benefit profile of recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a multicenter propensity score analysis. Crit Care 2015;19:78 10.1186/s13054-015-0810-3
    1. Yamakawa K, Ogura H, Fujimi S, et al. . Recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a multicenter propensity score analysis. Intensive Care Med 2013;39:644–52. 10.1007/s00134-013-2822-2
    1. Hayakawa M, Yamakawa K, Saito S, et al. . Recombinant human soluble thrombomodulin and mortality in sepsis-induced disseminated intravascular coagulation. A multicentre retrospective study. Thromb Haemost 2016;115:1157–66. 10.1160/TH15-12-0987
    1. Aikawa N, Shimazaki S, Yamamoto Y, et al. . Thrombomodulin alfa in the treatment of infectious patients complicated by disseminated intravascular coagulation: subanalysis from the phase 3 trial. Shock 2011;35:349–54. 10.1097/SHK.0b013e318204c019
    1. Wada H, Matsumoto T, Yamashita Y, et al. . Disseminated intravascular coagulation: testing and diagnosis. Clin Chim Acta 2014;436:130–4. 10.1016/j.cca.2014.04.020

Source: PubMed

3
Abonneren